Skip to main content
SIR 2025 Event Main banner
BSCI - Consideration Cases Ad 1
Merit/DPSSME Siege
Back

SIR 2025

Interventional Oncology

Scientific Session

Featured Abstract

Session: Interventional Oncology - Y90 2

Impact of Genetic Mutations on Response and Time to Progression After Radioembolization of Breast Cancer Liver Metastasis

Monday, March 31, 2025
3:00 PM – 3:09 PM CT
Location: Music City Center, 208 AB
Purpose: To evaluate the association between specific genetic mutations and clinical outcomes, including response rate and time to progression, in patients with breast cancer liver metastasis treated with Y-90 radioembolization.

Materials and Methods: This is a retrospective, single-institution study. 110 female patients with biopsy-proven breast cancer liver metastasis who underwent Y-90 radioembolization were included in this study. Genomic profiling was conducted using the MSK-IMPACT platform. Data was collected from electronic medical records (EMR) and Picture Archiving and Communication System (PACS) for patient demographics and treatment responses. Treatment responses were categorized as complete, partial, none, or progression. For patients with an initial response to treatment, both complete and partial, statistical analysis was performed to assess the correlation between genetic mutations and time to progression. Overall median survival using Kaplan Meier estimation was also performed and correlated to genetic mutations within the patient cohort. 17 patients died before progression could be assessed, and 6 patients have not yet been evaluated post-procedure.

Results: The overall median survival for the cohort was 32.8 months. Patients with the ERBB2 mutation showed the longest median survival (70.2 months), while those with the RAD21 mutation had the shortest median survival (25.5 months). KDM5C and CBFB mutations were associated with the highest response rates (100%, p = 0.00346 and p = 0.01462, respectively), while the H3C13 mutation was associated with the lowest response rate (0%, p = 0.00222). For patients with an initial response to therapy, the median time to progression was 32.8 months. The H3F3B mutation was associated with the longest time to progression (105 months), while the RUNX1 mutation was associated with the shortest time to progression (1.4 months).

Conclusion: Specific genetic mutations are associated with survival, response rates, and time to progression in breast cancer patients with liver metastasis treated with Y-90 radioembolization. This study underscores the significant potential genetic profiling can have in guiding individualized treatment plans and improving patient outcomes.